Agenda

D4: Data-Driven Drug Development conference is a 2-day meeting packed full of presentations, groups/panel discussions and round-table gatherings. The full agenda is below.

  • Day 1 focuses on Business and Strategy

  • Day 2 focuses on tackling Science, Practical and Tactical topics.


DAY 1: Wednesday, March 20th, 2019

BUSINESS AND STRATEGY


8.00 am REGISTRATION OPENS


8.55 am               WELCOME ADDRESS


9.00 am               KEYNOTE ADDRESS

The Big Picture: Why Getting Data Right is so Important for Pharma

· What are we fixing? What is the current problem? What are the drivers for change?

· What’s required to fully embrace data-driven decision making and drug development at executive level?

· Top-level strategies for implementing and improving the efficiency and effectiveness of data-driven approaches.

· Bottom-up: Considering the needs of end users and developing a clear vision & strategy to manage transition.

· What the main challenges in the context of data are cultural and ethical, not technical.

Martin Romacker, Principal Scientist, Data and Information Architecture, Roche


9.30 am               PRESENTATION: ANALYSIS AND INSIGHTS

A Critique of the Existing Data Life Cycle, How to Achieve Scale and a Vision for The Near- and Mid-Term Future

· Garbage in, garbage out: Why current spending on data capture and analysis can be flawed, and how to derive true value.

· The capture > storage > catalogue > analyse > share lifecycle, and how pharma can transition from data > information > knowledge > wisdom.

· The importance of data organization, enrichment and context in building robust processes and infrastructure that are more scalable.

· How to optimize the process for a variety and volume of use-cases, while reducing error rate and costs.

Dana Vanderwall, Director of Biology and Preclinical IT, Bristol-Myers Squibb


10.00 am             PRESENTATION

Practical Applications of AI in Pharma

There has been significant buzz and hype around AI in Pharma. With reports of many failures and below expectation deliveries, this presentation hopes to share what are some real practical applications of AI and what elements of AI matter when it comes to the specifics of life sciences.

Lawrence Ganti, Global President of Life Sciences and CEO, Americas, Innoplexus


10.30 am SPEED NETWORKING

Brief introductions with other meeting participants in a snappy, friendly format. A managed session, giving you the chance to quickly establish who else is in attendance and exchange business cards with potential partners and collaborators.


11.15 am             COFFEE AND NETWORKING


11.35 am             PRESENTATION: EMPIRICAL DATA ON DIRECTIONS AND TRENDS

Learning from Pharma Industry Metrics and Benchmarking from PRISME

· An overview on the activities and goals of PRISME – the Pharmaceutical R&D Information Systems Management Executives forum

· Directions and trends in R&D IT management and technology

· What the results mean for best practices to facilitate drug R&D in pharma

Martin Leach, VP, R&D, Global Operations and Global IT, Alexion Pharma


12.05 pm             TECHNOLOGY SPOTLIGHT SESSION

Towards an in silico biology framework for predicting biomarkers & novel targets for combinatorial immunotherapy

  • Immunotherapy can work miracles, when it works at all. Combining therapies in a rational way can expand reach and improve effectiveness, but also presents a host of new challenges.

  • Genialis Fusion is a platform for biomarker prediction and novel target discovery that relies on a key premise: integrating more diverse data and sources of information can yield more accurate models of complex biology

  • .We have previously applied this approach to various challenges in translational biology, clinical research, even agro-genomics. 

  • We have previously applied this approach to various challenges in translational biology, clinical research, even agro-genomics. 

  • Recently we decided to tackle the urgent need presented by the glut of trials in immune-oncology.

Rafael Rosengarten, CEO, Co-founder, Genialis, Inc.


 12.15 pm               ROUND TABLE DISCUSSIONS: SECURING BUDGET AND EXECUTIVE SUPPORT

Considerations for Making the Business Case, Managing Next Steps and Improving the Success of Implementation

Ideas and innovation are important, but with pharma and data there is a clear disconnection between ideas and business reality. Making change happen in a fast-moving organization is difficult.

Improving (often) antiquated systems and processes for biodata collection, management, analysis and interpretation so that they are fit-for purpose in the new-age of data will mean winning the business case for investment with executive teams.

Attendees will break off into round-table discussions to discuss how to build, make and win the business case for investment and change.  Notes will be taken, and the output from this session will be captured and structured into a summary report for attendees.

Points for discussion will vary, but might include:

· Overall challenges, risk factors and lessons learned in winning the business case for such projects.

· What are the criteria/tenets for making the business case

o   Scale and the importance of adaptive, sustainable infrastructure.

o   Supplier/partner considerations.

· Learning from experience – factors that led to a successful outcome

· Lessons learned re. culture and how change was received within the organisation.

· How to demonstrate/project ROI.


1.00 pm           LUNCH AND NETWORKING


 1.50 pm             PRESENTATION: MAKING DATA FAIR

What to do About FAIR…

In the experience of most pharma professionals, FAIR remains fairly abstract, bordering on inconclusive. This session will outline specific case studies – real problems with real data, and address opportunities and real concerns.

· Why making data Findable, Actionable, Interoperable and Reproducable is important.

· “If FAIR data has a value, somebody would pay for it”. Could it be that the value is not worth the cleansing? Contrasting the ideal with the reality.

· Moving forward: How can FAIR work best in a commercial context?

 Tom Plasterer, US Cross-Science Director, R&D Information, AstraZeneca


 2.20 pm             TECHNOLOGY SPOTLIGHT SESSION

Accelerating drug development: The role of IT as a strategic partner

· Unifying data to accelerate biologics R&D

· How leading biopharma companies transition to a unified data infrastructure

· Building a case for investing in data management and collaboration.

Sajith Wickramasekara, CEO and Co-Founder, Benchling 


2.30 pm PRESENTATION: SUPPORTING STRATEGIC DECISION-MAKING RELATING TO AI

Crash Course in AI for Leadership Teams in Pharma

This session will simplify key AI concepts to help leadership team to connect the dots in the value chain in their organization. It will help attendees appreciate the hype and hope areas of AI, enabling senior business, IT, data and research leaders to make better strategic decisions around the use of AI in various aspects of drug development. The session will both demystify AI and debunk AI myths that prevent organizations and senior-level people from moving forward in making the right decisions.

Bino John, Associate Director, AstraZeneca


3.00 pm PRESENTATION: BUILDING DATA VALUE VIA ML/AI TECHNOLOGIES

Capitalizing on The Emerging Role Of ML/AI-Driven Technologies as Relevant for Data Capturing and Processing to Build Value

· Roles for AI/ML in optimizing each element of an improved data lifecycle, and what this means for making a business case and managing change.

· Why improvements in ML and adoption of ML approaches are a necessity for pharma in generating business-wide value and ROI.

· Why organization/structuring of data and fully leveraging ML go together.

· Careful consideration of end users and culture through the adoption of ML.

Peter Henstock, Senior Data Scientist, Machine Learning, Software Engineering, Statistics and Visualization, Pfizer


3.30 pm COFFEE AND NETWORKING


4.00 pm              PRESENTATION: VALUING DATA

How to Assess the True Value of Bio-Data in the Context of Pharma

· Why has it become increasingly important to assess the value of data? The important questions to ask.

· Factors that influence the value of data.

· Getting involved: Next steps in a collaborative experiment to build a model for assessing the value of data.

Andrea Splendiani, Associate Director, Information Systems, Novartis


4.30 pm INNOVATION SHOWCASE

The innovation showcase is an interactive session, designed to deliver you the most innovative breakthrough technologies affecting data-driven drug development. Each presentation lasts 10 minutes, and at the end of the session, the audience vote for the technology/presentation that they think will have the greatest impact.

Talk 1: Applying artificial intelligence at every stage of discovery - Gabe Musso, Chief Technology Officer, Biosymetrics

Talk 2: Illuminating the Path Towards Precision Medicine with Apollo and UK Biobank. - Maria Simbirsky, Senior Platform Engineer, AI., DNA Nexus

Talk 3: Ligand Design at Scale: Automated design and evaluation of large compound libraries with physics-based modeling and machine learning - Melissa R. Landon, Director, Applications Science, Schrodinger

Talk 4: AI and the Rx life cycle - Richie Bavasso, Chief Executive Officer, nQ-Medical Inc


5.15 pm              PANEL DISCUSSION: DATA VALUE, THE DATA ECOSYSTEM AND TAKEAWAYS

A summary of the day’s discussion and take-home intelligence/insights. Topics will be taken from the audience, but might include:

Data Value

· How can you define metrics for the “value” of a dataset?

· Cracks between departmental cultures: who understands how much it costs to cleanse data? Who does it?

Pharma Ecosystem Alignment in a New Data-Driven World

· Regulators: Data calls for iterations and speed. But regulation struggles with fast pace. How to manage a potential disconnect, and what should the future look like?

· Privacy issues: The world of biodata/AI is exploratory. Most consent is for “specific purposes”. How do the two fit together?

· Future considerations: Do we need a new, overall model for data/information in medicine, if it’s use/housing not going to be limited to pharma anymore?

Capturing the Main Takeaways and Useful Next Steps from Today

· A discussion of whether the meeting met objectives. If not, what’s missing – a brief discussion on those points.

· What would be the useful next steps, focus areas and/or meet-ups?

Dana Vanderwall, Director of Biology and Preclinical IT, Bristol-Myers Squibb

Martin Leach, VP, R&D, Global Operations and Global IT, Alexion Pharma

Peter Speyer, Head of Digital, Medical and RWE Solutions, Novartis


5.45 pm            CLOSING REMARKS FROM CHAIR


5.50 pm           DRINKS AND NETWORKING


7.00 pm DINNER

Dinner at a local restaurant for those who have signed up - please sign up at the registration desk on the day. A final opportunity to network with other attendees in an informal setting.


DAY 2: Thursday, March 21st, 2019

SCIENCE, PRACTICAL AND TACTICAL


9.00 am WELCOME


9.05 am              OPENING ADDRESS

Data Driven Drug Development

· The importance of taking a scientific approach to industry challenges.

· How have data driven approaches developed throughout the field of genomics.

· What are the main objectives of the day.

Brian Dougherty, Executive Director, Translational Science Oncology, AstraZeneca


 9.30 am              PANEL DISCUSSION

How Did We Get Here, Where Do We Go Now?

· Why is there such a difference in approach to applied human genetics within pharma?

· If pharma is a copycat industry, what is going to be the big success that forces the rest to follow?

· How do you scale up efficiently, and begin to seriously look at integrating multi-omic and real-world data?

Justin Johnson, Associate Director and Principal Translational Genomic Scientist, AstraZeneca

Nadeem Sarwar, President, AIM, Eisai

Michelle Penny, Director Computational Biology and Genomics, Biogen

Mera Tilley, Head of Precision Medicine, Goldfinch Bio


 10.00 am            SPEED NETWORKING

A managed session, giving you the chance to quickly establish who else is in attendance and exchange business cards with potential partners and collaborators. Morning refreshments will also be provided.


10.45 am COFFEE AND NETWORKING


11.00 am            PANEL DISCUSSION

Panning for Gold

· Separating the ‘useful’ from the ‘interesting’ in research.

· How do you turn Machine Learning and Big Data in pharma, from sexy to applicable?

· Solving data access challenges and understanding how to scale up and generate the right kinds of data.

Robert Yang, Computational Biology Group Leader, Celgene

Bin Li, Director, Computational Biology, Takeda

Pankaj Agarwal, Senior Fellow, Computational Biology, Functional Genomics, GSK


11.30 am             TECHNOLOGY SPOTLIGHT

Managing Bioassay Metadata with BioAssay Express

Samantha Jeschonek, Research Scientist, CDD – Collaborative Drug Discovery


11.40 am CASE STUDY

Applied Genomics in Drug Discovery and Development

Practical examples of successful integration of genetic analysis in drug development and discovery. Detailing the successes in eliminating inefficiencies, and opportunities around biomarker identification, target discovery, translational research, and trial enrolment and stratification.

Janna Hutz, Senior Director and Head of Human Biology & Data, Eisai


12.10 pm NETWORKING LUNCH


1.10 pm             PANEL DISCUSSION

Making Clinical Trials Work for You

· What opportunities are in the freezer full of samples?

· What will be admissible to support regulatory approval?

· How can you make effective use of data to bring down the cost and increase the success of clinical trials?

Charlie Paulding, Director Predictive Medicine Genetics & Translational Medicine, Regeneron

Michael Pacanowski, Associate Director for Genomics and Targeted Therapies, FDA

Liron Walsh, Vice President of Translational and Clinical Nephrology, Goldfinch Bio

Jeffrey Waring, Senior Director, Pharmacogenetics and Human Genetics, Genomics Research Center, abbvie


1.40 pm              DISCUSSION/ROUND-TABLE GROUP SESSIONS

Less Talks, More Action

The afternoon session will build on the day’s discussions and presentations. The meeting will split into groups to discuss discreet topics to identify common challenges, potential solutions, and actionable next steps.

1.40 pm Overview of the session and splitting into groups.

1.50 pm Round-table discussions on Deriving Actionable Data From Clinical Trials; Sequencing at Scale; Regulatory Approval for Genomic and Targeted Therapies; Oncology; Translation.

2.50 pm Present main findings from each group. These work from each group will also be turned into a report to be circulated post-event to attendees.


 3.30 pm              CLOSING REMARKS